A team from the Institute of Molecular and Cellular Pharmacology (Valbonne – Sophia Antipolis), led by Inserm researcher Barbara Bardoni, has revealed the key role of a protein, PDE2A, in the development of Fragile X syndrome. A discovery that opens up the possibility of identifying new treatments in the near future.

Tue 23 Oct 2018 – 10:30